PCSK9 inhibitor
A drug class that blocks the PCSK9 protein so liver cells clear more LDL cholesterol from the blood.
As defined in Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]
Where it comes up · 1
Most important claims · 4 of 4Search all claims for “PCSK9 inhibitor” →
- A population with a PCSK9 gene mutation that prevents production of the protein had about an 88 percent lower lifetime risk of cardiovascular disease over 15 years of study, which led drug developers to replicate the advantage with PCSK9 inhibitors.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]
- LDL cholesterol accumulates in the vasculature over time until it causes a blockage, which produces a heart attack or stroke; most middle-aged adults carry a 30 to 50 percent lifetime probability of one between ages 40 and 80, which statins and PCSK9 inhibitors could cut to under 10 percent.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]
- PCSK9 lowering is nearly a free lunch because LDL cannot be pushed to zero in animal models beyond 80 to 90 percent, and people with natural PCSK9 deficiency live long healthy lives, suggesting low LDL carries little harm.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]
- Because PCSK9 has an asymmetric benefit and risk profile, its long-run patient count and revenue should exceed GLP-1s, but adherence is harder since high LDL produces no felt symptoms.Alex Karnal - The Trillion-Dollar Health Revolution - [Invest Like the Best, EP.468]